Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Xilio Therapeutics reported a quarterly loss of $0.20 per share, better than the Zacks Consensus Estimate of a loss of$0.22, and an improvement from a loss of $0.64 per share a year ago, indicating an earnings surprise of 9.09$1.72 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 23.72%, compared to zero revenues a year ago [2] - Xilio Therapeutics shares have declined approximately 11.5% since the beginning of the year, while the S&P 500 has decreased by 4.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.34 on revenues of$42 million, and for the current fiscal year, it is -$0.40 on revenues of$64.25 million [7] - The estimate revisions trend for Xilio Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Xilio Therapeutics belongs, is currently in the top 29% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]